Table 1. Epidemiological parameters considered in the analytical model for the Brazilian Amazon.
| Parameter | Base-case | Variation | Distribution | Source |
|---|---|---|---|---|
| Proportion of febrile patients given a malaria test who test positive for malaria | 0.088a | (0.078–0.170)b | Beta (α: 2,503 and β: 25,903) | [15] |
| Proportion of malaria patients who have vivax malaria | 0.792a | (0.738–0.994)b | Beta (α: 1,982 and β:521) | [15] |
| Proportion of male patients with vivax malaria among all male patients with vivax malaria | 0.601a | (0.601–0.602)b | Beta (α:1,191 and β: 791) | [15] |
| Proportion of female vivax malaria patients who are pregnant | 0.031a | (0.028–0.036)b | Beta (α:785 and β: 24,508) | [15,16] |
| Proportion of female patients with vivax malaria who have G6PD enzyme activity less than 30% of normal | 0.025a | (0.020–0.039)b | Beta (α: 16 and β: 637) | [14] |
| Proportion of male patients with vivax malaria who have G6PD enzyme activity less than 30% of normal | 0.025a | (0.021–0.037)b | Beta (α: 25 and β: 965) | [14] |
| Sensitivity (SD Biosensor Standard G6PD test) | 1.00 | (0.938–1.00)c | Beta (α: 58 and β: 1) | [8] |
| Specificity (SD Biosensor Standard G6PD test) | 0.978 | (0.970–0.985)c | Beta (α: 1,599 and β: 36) | [8] |
| Proportion of patients with enzyme activity less than 30% of normal hospitalized after treatment with PQ | 0.134d | (0. 089–0.162)d | Beta (α:94 and β: 606) | [4,14] |
a: parameter calculated based on data from both municipalities
b: calculated variation considering the data from the municipalities separately, represents the variation between the two assessed municipalities
c- variation based on the 95% confidence interval of the measure
d: Proportion estimated based on data from the literature and from the Safeprim study (S1 Table).